COPENHAGEN, Denmark, Sept. 26, 2023 /PRNewswire/ -- Acesion Pharma ('Acesion' or 'the Company'), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ('AF'), the most common cardiac arrhythmia, today announces that it has successfully closed an oversubscribed €45M Series B financing round. The equity financing was co-led by new US-based investors Canaan and Alpha Wave and with participation by the Global BioAccess Fund, as well as existing investor Novo Holdings.
Danish pharmaceutical firm Acesion Pharma has reported positive pre-clinical data for its second-generation oral SK channel inhibitor AP31969.